Morningstar7d
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2 ...
Pharmabiz1mon
Kelun-Biotech’s novel ADC drug SKB445 receives NMPA approval to treat advanced solid tumours
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a holding subsidiary of Kelun Pharmaceutical, announced that the company has received a clinical trial notice approving the investigational new drug ...
pharmaphorum2d
Kelun's MSD-partnered TROP2 drug gets first okay in China
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).